SAN DIEGO, Feb. 14, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J. Dunn, M.S., M. Ed. to Senior Vice President of Commercial Operations.  Ms. Dunn succeeds Edwin Hendrick, who resigned to pursue other endeavors. 

Ms. Dunn has served as Biocept's Vice President of Commercial Operations since October 2018.  Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix.  She holds an M.A. in education from Stanford University, and M.S. in Biology and B.S. in Biochemistry and Cell Biology from the University of California, San Diego.

"Cory has done a fantastic job over the past several years in expanding our Target Selector™ strategy into urology and oncology, and we are delighted that she will head our commercial operations," said Michael Nall, Biocept's President and CEO.  "The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial progress.  I want to thank Edwin Hendrick for his leadership and dedication to Biocept and we wish him all the best in his future endeavors."

"I look forward to taking on this new challenge and am enthusiastic about working with the commercial team to expand Biocept's reach and the universe of patients who can benefit from our Target Selector™ testing," said Ms. Dunn.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer.  The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA).  With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the expansion in the number of patients that will have an opportunity to benefit from our liquid biopsy testing platforms, our ability to improve the outcomes of patients diagnosed with cancer, and the potential clinical utility of our proprietary technology platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Investors:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

Media:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378

SOURCE Biocept, Inc.

Related Links

http://www.biocept.com